Avantor, Inc.
At today's price, Avantor, Inc. (AVTR) is priced for +6.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
At $9.57 the price pays about 16x mid-cycle operating income, implying roughly 4.5% operating growth a year for five years. That is a modest bar for a lab-supplies and bioscience platform, and the reverse-DCF range collapses essentially to the current price, so the market is paying about what a base-case recovery is worth. The balance sheet is the story. Net debt of roughly $3.56 billion sits against trailing operating income that is negative once the cycle runs through, and management has put
Is AVTR overvalued? See what's priced in →
415 institutional managers reported holding AVTR in 13F filings for the quarter ended 2026-03-31. 79 opened new positions that quarter. Held by Dodge & Cox, Vanguard Group, BlackRock, among others. On the short side, 44.0M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (4.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AVTR's share count grew 16% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at AVTR over the trailing three years: 2025: 11 buys totaling $8.76M; 2026: 3 buys totaling $2.40M. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AVTR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | -6.8% | -0.9% |
| 2023-10-28 | -8.7% | +28.0% |
| 2024-02-15 | +8.6% | +1.0% |
| 2024-04-27 | -4.8% | -11.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AVTR's latest 8-K filings: 2026-05-12 (items 5.07, 9.01); 2026-04-29 (items 2.02, 9.01); 2026-04-23 (items 5.02, 7.01, 9.01); 2026-04-01 (items 5.02, 7.01, 9.01); 2026-02-11 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.